Condition

RET Gene Mutation

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting1

Common interventions7

Lead sponsors shown4

Clinical trials

4 shown

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCNCT06109558 · 2023-12-31

RECRUITING

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted TherapiesNCT05370469 · 2022-08-25

ACTIVE_NOT_RECRUITING

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsNCT04161391 · 2019-12-06

TERMINATED

Continued Access to RXDX-105NCT03784378 · 2018-12-14

COMPLETED

Common interventions

Fitbit SenseDEVICE1 LMV-12(HE003)DRUG1 RX CapDEVICE1 RXDX-105DRUG1 Sensus Smartwatch ApplicationOTHER1 SurveysOTHER1 TPX-0046DRUG1

Leading sponsors

Hunan Province Tumor Hospital 1 Memorial Sloan Kettering Cancer Center 1 Turning Point Therapeutics, Inc. 1 University of Virginia 1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

RECRUITING1

TERMINATED1

Phase mix

PHASE13

PHASE22

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.